Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R1441G) transgenic mouse
- 1 August 2013
- journal article
- Published by Elsevier in Neuroscience Letters
- Vol. 549, 57-62
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson’s diseaseJournal of Neuroinflammation, 2012
- Global Profiling of Reactive Oxygen and Nitrogen Species in Biological SystemsJournal of Biological Chemistry, 2012
- Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the diseaseBritish Journal of Pharmacology, 2011
- Apocynin administration does not improve behavioral and neuropathological deficits in a transgenic mouse model of Alzheimer's diseaseNeuroscience Letters, 2011
- Anti-inflammatory drugs and risk of Parkinson diseaseNeurology, 2010
- The Role of NADPH Oxidase 1–Derived Reactive Oxygen Species in Paraquat-Mediated Dopaminergic Cell DeathAntioxidants & Redox Signaling, 2009
- Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's diseaseNature Neuroscience, 2009
- Leucine-Rich Repeat Kinase 2 Mutations and Parkinson's Disease: Three QuestionsASN Neuro, 2009
- Bioavailability of apocynin through its conversion to glycoconjugate but not to diapocyninPhytomedicine, 2008
- Apocynin: Molecular AptitudesMediators of Inflammation, 2008